🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 409306

Found 23 matching trials

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

PHASE1

The main objective of this trail is to investigate if and to what extent BI...

Status

Completed

Location

Collaborative Neuroscience Research, LLC

Start Date

2020-12-01

Trial ID

NCT04602221

Treatments Being Tested

Lamotrigine BI 409306 Placebo BI 425809

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

PHASE2

The objective of the study is to investigate the efficacy, safety and toler...

Status

Terminated

Location

Alea Research

Start Date

2017-12-07

Trial ID

NCT03351244

Treatments Being Tested

BI 409306 Placebo

Safety Tolerability and Pharmacokinetic of BI 409306

PHASE1

The primary objective of the current study is to investigate the safety and...

Status

Completed

Location

1289.1.1 Boehringer Ingelheim Investigational Site

Start Date

2011-04-01

Trial ID

NCT01343706

Treatments Being Tested

Placebo Placebo BI 409306 BI 409306

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

PHASE1

Single site, parallel-group, double-blind trial of low or high dose of BI 4...

Status

Completed

Location

University of California San Diego

Start Date

2015-04-15

Trial ID

NCT02392468

Treatments Being Tested

Placebo matching BI 409306 25 mg Placebo matching BI 409306 50 mg BI 409306 25 mg BI 409306 50 mg

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

PHASE2

The objective of the study is to investigate the efficacy, safety and toler...

Status

Completed

Location

K and S Professional Research Services, LLC

Start Date

2014-11-10

Trial ID

NCT02281773

Treatments Being Tested

BI 409306 100 mg QD BI 498306 50 mg QD Placebo BI 498306 25 mg QD BI 409306 10 mg QD

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

PHASE2

This is a study in people between 16 and 30 years of age who have a specifi...

Status

Terminated

Location

ProScience Research Group

Start Date

2017-09-29

Trial ID

NCT03230097

Treatments Being Tested

BI 409306 Placebo

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

PHASE1

The primary objective of this trial is to assess the effect of BI 409306 on...

Status

Completed

Location

Humanpharmakologisches Zentrum Biberach

Start Date

2019-05-09

Trial ID

NCT03934203

Treatments Being Tested

BI 409306 Moxifloxacin Placebo matching to BI 409306

BI 409306 Cardiac Safety Trial in Healthy Volunteers

PHASE1

This trial will be conducted to further evaluate, in a controlled setting, ...

Status

Completed

Location

1289.28.1 Boehringer Ingelheim Investigational Site

Start Date

2015-05-04

Trial ID

NCT02438683

Treatments Being Tested

BI 409306 BI 409306 Placebo

Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers

PHASE1

Due to the exploratory nature of this trial, there is no primary objective ...

Status

Completed

Location

1289.3.1 Boehringer Ingelheim Investigational Site

Start Date

2011-12-01

Trial ID

NCT01493570

Treatments Being Tested

BI 409306 Placebo

Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers

PHASE1

The primary objective of this trial is to investigate the relative bioavail...

Status

Completed

Location

Humanpharmakologisches Zentrum Biberach

Start Date

2017-05-30

Trial ID

NCT03151499

Treatments Being Tested

BI 409306 Rifampicin

Previous Next